Lebrikizumab Therapy Improved QoL, Mental Health Outcomes in Patients with Atopic Dermatitis; In a study of persons with moderate-to-severe atopic dermatitis, lebrikizumab monotherapy for 16 weeks resulted in improved quality of life and mental health.

Press/Media

Period10 Sep 2024

Media coverage

1

Media coverage

  • TitleLebrikizumab Therapy Improved QoL, Mental Health Outcomes in Patients with Atopic Dermatitis; In a study of persons with moderate-to-severe atopic dermatitis, lebrikizumab monotherapy for 16 weeks resulted in improved quality of life and mental health.
    Media name/outletPatient Care
    Country/TerritoryUnited States
    Date10/09/24
    PersonsPeter Lio